Management of immune checkpoint inhibitor-associated myocarditis: An overview
Thorough patient history and various diagnostic modalities, like imaging and biopsy, may be useful in diagnosing ICI-associated myocarditis, according to a narrative review published in the JAMA Cardiology.
In the last few years, Immune checkpoint inhibitors (ICIs) are a new class of immunotherapy drugs that are beneficial for treating different types of cancers like metastatic melanoma, non-small lung cancer, or renal cell carcinoma. These drugs work by blocking checkpoint proteins from binding with their partner proteins.
But, the immune checkpoint inhibitor-associated myocarditis has led to a significant and possibly deadly side-effect. Hence, identifying, diagnosing, and managing ICI-associated myocarditis has created new difficulties for the practicing medical professional.
In this study Lehmann L et. al conducted a current literature review on ICI-associated myocarditis with an aim to provide a standardized diagnostic and therapeutic approach for patients with suspected ICI-associated myocarditis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.